Skip to main content
Premium Trial:

Request an Annual Quote

Elixir Pharmaceuticals Closes Merger, $17 Million VC Funding

 

 

NEW YORK, February 12 -- Centagenetix and Elixir Pharmaceuticals today announced the completion of a merger initiated in January and a $17 million injection of venture capital.

 

The new company, called Elixir Pharmaceuticals, will be based in Cambridge, Mass., and led by Edward Cannon, president and CEO. The merger was an all-stock transaction.

 

Elixir is creating a technology platform for drug discovery targeting aging in laboratory organisms, while Centagenetix has a portfolio of population association studies of genes and gene variants from individuals of extreme longevity and vitality.

 

The new company will receive venture funding through the initial closing of a $17 million Series B round of financing led by MPM Capital of Boston, LP Arch Venture Partners of Chicago, and Oxford Bioscience Partners of Boston. 

 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.